Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PTLA

Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis

Portola Pharmaceuticals logo

About Portola Pharmaceuticals Stock (NASDAQ:PTLA)

Key Stats

Today's Range
$18.03
$18.03
50-Day Range
$18.03
$18.03
52-Week Range
$5.31
$31.73
Volume
N/A
Average Volume
3.17 million shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PTLA Stock News Headlines

Portola Middle
50-year Wall Street legend: “Sell this tech stock NOW”
Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.
Fault lines in Portola Valley
Portola-Butler Continuation High School
Eagle Pharmaceuticals
See More Headlines

PTLA Stock Analysis - Frequently Asked Questions

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.14. The firm's revenue for the quarter was up 18.9% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL) and Geron (GERN).

Company Calendar

Last Earnings
5/11/2020
Today
11/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTLA
Fax
N/A
Employees
324
Year Founded
N/A

Profitability

Net Income
$-290,660,000.00
Net Margins
-232.73%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$116.64 million
Book Value
$1.67 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.42 billion
Optionable
Optionable
Beta
2.32
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:PTLA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners